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layer-	 is	 composed	 from	 the	 photoreceptors:	 the	 rods	 and	 the	 cones,	 which	 are	 light-













Retinitis	 pigmentosa	 is	 composed	 of	 inherited	 dystrophic	 retinal	 diseases,	 which	 are	
characterized	by	progressive	degeneration	 and	dysfunction	of	 the	 retina.	 The	 terminology	
“retinitis”	is	not	accurate,	since	it	is	not	an	inflammatory	disease.	Other	terms	like	“rod-cone	
dystrophy”,	“inherited	retinal	dystrophy”	or	“pigmentary	retinopathy”	may	be	used.	




(about	20	–	30%	of	 the	 cases).	 There	are	more	 than	30	RP-associated	 syndromes	 (4).	 The	
Usher’s	 syndrome	 (associated	 with	 hearing	 loss	 and	 ataxia)	 (5)	 and	 the	 Bardet-Biedl	
syndrome	(associated	with	obesity,	cognitive	impairment,	polydactyly	and	renal	disease)	are	











constriction	 of	 the	 visual	 fields.	 First,	 the	 patient	 will	 notice	 a	 loss	 of	 the	mid-peripheral	
visual	 field,	 which	will	 evolve	 to	 the	 loss	 of	 far-peripheral	 vision.	 Then,	 they	will	 develop	
tunnel	vision	and	eventually	lose	their	central	vision	about	age	30	or	much	earlier	depending	
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The	 diagnostic	 of	 retinitis	 pigmentosa	 can	 be	 done	with	 the	 combination	 of	 the	 patient’s	
history	 and	 some	 complementary	 examination.	 One	 of	 the	most	 important	 assessment	 is	
done	with	the	fundus	exam,	on	which	we	can	see	pigmentary	changes,	as	dark	spots	in	the	
periphery	 of	 the	 retina,	 and	 pallor	 on	 the	 optic	 nerve.	 A	 patient	 with	 RP	 will	 have	 a	
constrictive	 visual-fields	 measured	 by	 the	 Goldman	 perimetry	 and	 the	 ERG	 (electro-
retinogram;	which	measures	the	electrical	response	of	the	retina	to	light	stimuli)	will	show	
reduced	response	amplitudes	and	a	delay	in	their	timing	(6).		
No	 approved	 treatment	 currently	 exists	 (7)	 and	 this	 disease	 often	 leads	 to	 blindness.	







Initially,	 it	 was	 thought	 that	 retinal	 photoreceptor’s	 death	 was	 due	 to	 mechanism	 like	
apoptosis	 (9).	 However,	 neurodegeneration	 in	 photoreceptor	 seems	 to	 be	 a	much	 slower	
mechanism	 than	 apoptosis	 and	 does	 not	 involve	 the	main	 actors	 inducing	 apoptosis	 (10).	
Distinct	pathways	are	implied.	In	fact,	studies	show	that	the	underlying	mechanism	of	retinal	
degeneration	is	more	complex.	
Retina	 from	 a	 mouse	 model	 with	 deficient	 gene	 for	 the	 ß	 subunit	 of	 phosphodiesterase	
(PDE6ß),	Rd1	mice,	 are	 habitually	 used	 for	 the	 investigation	 on	 retinal	 degeneration	 (11).	
Many	cellular	pathways	were	observed	to	be	activated	or	altered	during	the	photoreceptor	
degeneration	 process.	 For	 instance,	 it	 was	 seen	 that	 cGMP	 (Cyclic	 guanosine	
monophosphate)	and	PKG	(Protein	kinase	G);	which	are	two	well-known	regulators	of	intra-
cellular	activity,	had	an	 increased	 level	 in	 these	Rd1	mice,	and	that	 their	 inhibition	 in	vitro	
could	 lead	 to	 moderate	 cell	 rescue	 (12).	 Other	 processes	 like	 calpain-type	 protease	
activation	 (13),	 increased	 calcium	 (14)	 and	 oxidative	 stress	 (15)	 are	 also	 fairly	 suspected.	
Moreover,	an	increased	PARP	(-protein	involved	in	the	DNA	repair)	level	was	also	identified	
in	 Rd1	 mice	 (16)	 and	 was	 therefore	 a	 well-studied	 protein	 for	 the	 retinal	 degeneration.	
Therefore,	 an	 alternative	molecular	 pathway	 to	 cell	 death	 degeneration	 involving	 CREB	 (-





of	 BMI1	 (polycomb	 group	 protein	 regulating	 proliferation)	 could	 lead	 to	 a	 significant	 	 cell	
rescue.		Indeed,	some	cell	cycle	protein	may	have	a	second	role	in	certain	post-mitotic	cells	













are	 a	major	 class	 of	 regulatory	molecule	 in	 animals	 and	 plants	 (24).	 They	 can	 control	 the	









































One	 of	 the	 first	 steps	 was	 to	 amplify	 our	 DNA	 plasmids	 expressing	 the	 miR-31	 coding	
sequence	and	GFP	control	into	a	lot	bigger	amount	in	the	process	called	transformation.	
For	bacterial	transformation,	we	used	the	DH5	alpha	electro	competent	cells.	1	µL	of	each	
plasmid	was	 incubated	with	 50	 µL	 aliquot	 of	 DH5	 alpha,	well	mixed	with	 gentle	 agitation	
before	electroporation	 (with	BioRad	Micropulser™).	After	1	h	 incubation	of	 the	mixture	 in	
minimal	medium	 (S.O.C),	20	µL	of	 the	cell	 solution	were	plated	on	LB	agar	with	ampicillin	
antibiotics	 for	 selection	 of	 successful	 transformants.	 For	 homogeneous	 distribution	 of	 the	
cell	suspension	on	the	LB	agar	plate,	we	added	autoclaved	glass	beads	(4	mm	diameter)	and	





The	next	day,	we	used	a	pipette	 tips	 to	carefully	pinch	a	 single	colony	and	 transfer	 it	 into	
tube	 containing	 a	 mix	 of	 2	 mL	 of	 LB	 medium	 and	 2	 µL	 of	 ampicillin.	 The	 mix	 was	 then	
incubated	at	37°C	incubator,	300	rpm	for	more	than	6	hours.	1	mL	of	the	mini	culture	was	


























turn	 per	 minute	 and	 then	 re-suspended	 in	 5	 mL	 of	 DMEM	 medium.	 We	 then	 took	 the	
necessary	proportion	of	volume,	according	to	the	desired	passaging,	to	seed	in	a	new	flask.	





Transient	 transfection	 is	 the	 introduction	of	 purified	DNA	 into	 a	 cell.	 It	 can	 be	 performed	
through	different	techniques	such	as	electroporation,	calcium	phosphate	or	lipofection.	We	
used	this	last	technique	for	our	transfection:	a	cationic	lipid	was	mixed	with	the	DNA	to	form	
liposome,	 this	 complex	will	 then	 fuse	with	 the	membrane	of	 the	 target	 cell,	 and	drop	 the	
DNA	material	inside.	
About	12	to	24	hours	before	the	transfection,	1.2x	105	and	6x104	cells	were	seeded	on	12-
well	 plates	 (in	 2	 mL	 of	 growth	 medium)	 or	 24-well	 plates	 (1	 mL	 of	 growth	 medium)	
respectively,	so	that	the	confluence	will	be	about	70-80%	during	the	transfection.		
The	 transfection	 was	 performed	 in	 triplicate	 for	 each	 plasmid,	 using	 the	 HBSS	 buffer	 as	
control.	 Cells	 were	 transfected	 with	 lipofectamine®	 2000	 transfection	 reagents	 and	
lipofectamine®	3000	transfection	reagents	according	to	the	manufacturer	protocol.	Briefly,	
the	actual	cell	medium	in	the	well	plate	was	aspirated	and	replaced	with	OPTI-MEM	which	is	




DNA	 (and	P3000	 reagents)	was	 added	drop	by	drop	 in	 the	 lipofectamine	 tube,	which	was	
incubated	during	5	–	10	minutes	at	room	temperature.	After	the	DNA-lipid	complex	was	well	
formed,	 100	 µL	 of	 this	 mix	 was	 gently	 distributed	 in	 the	 corresponding	 well	 and	 then	
incubated	at	37°C	so	that	the	DNA	complex	could	be	fully	 integrated	and	expressed	 in	the	





The	 cells	 were	 harvested	 by	 scraping,	 and	 transferred	 into	 a	 1.5	 mL	 micro	 centrifuge	
Eppendorf	 tube.	 Then	 pelleted	 at	 300	 g,	 4°C	 during	 10	 minutes.	 Cells	 were	 washed	 in	
phosphate	 buffer	 saline	 (PBS)	 500	 µL,	 pelleted	 as	 above,	 and	 lysed	 in	 150	 µL	 of	
Radioimmunoprecipitation	 assay	 (RIPA)	 Lysis	 Buffer	 (10	mM	Tris	 [pH	 8],	 1	mM	EDTA,	 140	
mM	 NaCl,	 1%	 Triton,	 0,1%	 SDS,	 0,1%	 Na-deoxycholate)	 with	 cell	 lysis	 supplements	 (1%	
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proteases	 inhibitors	 cocktails,	 1%	 phosphatases	 inhibitors,	 1	 mM	 phenylmethylsulfonyl	
fluoride	(pmsf)).	The	cells	were	lysed	up	and	down	with	pipette	and	then	incubated	on	ice	
for	 30	 minutes	 with	 constant	 vortexing	 each	 5	 to	 7	 minutes.	 The	 cell	 debris	 was	 then	
pelleted	 by	 centrifugation	 16’000	 g,	 at	 4°C	 during	 10	 minutes.	 The	 supernatant,	 which	





Bicinchoninic	 acid	 assay	 (BCA	 assay)	 is	 a	 colorimetric	 technique	 that	 measure	 the	 total	
concentration	 of	 protein	 in	 a	 solution.	 Our	 BCA	 assay	 was	 done	 in	 a	 96-well	 transparent	
plate.	First,	we	prepared	the	standard	solution,	with	a	serial	dilution	from	the	stock	solution	
at	 2	 µg/µL	 bovine	 serum	 albumin	 (BSA)	 diluted	 in	 our	 RIPA	 lysis	 buffer,	 so	 that	 the	 BSA	
concentration	 was	 known,	 in	 a	 final	 volume	 of	 50	 µL.	 Next,	 the	 sample	 dilution	 was	
performed,	with	5	µL	of	sample	diluted	in	45	µL	of	RIPA	lysis	buffer.	All	the	solutions	were	
then	well	mixed	up	and	divided	in	two,	by	pipetting	25	µL	of	each	well	side	down	to	a	clear	
well,	 for	 a	 final	 volume	 of	 25	 µL.	 BCA	 reagents	 mix	 of	 200	 µL	 were	 added	 in	 each	 well,	
followed	by	a	gently	 shaking	during	30	seconds	at	 room	temperature,	and	 then	 incubated	





Western	 blot	 is	 a	 biomoecular	 technique	 that	 allows	 the	 detection	 and	 identification	 of	
proteins	in	a	certain	solution.	It	uses	antibodies:	the	primary	antibody,	which	is	specific	for	a	
protein	of	 interest,	and	the	secondary	antibody,	which	binds	the	first	one	and	permits	the	









Proteins	 were	 transferred	 into	 a	 nitrocellulose	membrane	 during	 90	minutes	 at	 500	mA,	
immersed	 in	a	transfer	buffer	(for	1	L:	Ethanol	20%,	0,58	g	Tris	 (48	mM),	0,29	g	Glycin	(39	
mM),	SDS	10%).	For	 this,	 the	membrane	was	placed	next	 to	 the	gel,	 sandwiched	between	
blotting	paper	and	sponges	and	clamped	tightly	between	solid	brackets.	The	nitrocellulose	




To	 prevent	 non-specific	 interactions,	 it	 was	 further	 incubated	 1	 h	 with	 odyssey	 blocking	
buffer	 (PBS	 3:1	 TBS)	 at	 room	 temperature	 to	 prevent	 non-specific	 interactions.	 The	
































The	 total	 RNA	 was	 extracted	 using	 RNAzol®	 reagent	 (Sigma)	 according	 to	manufacturer’s	
instructions.	Briefly,	cells	were	thaw	from	-80°C	and	lyzed	in	200	µL	RNAzol	RT	and	then	put	




to	 the	 RNA	 pellet	 was	 solubilized	 in	 15	 µL	 RNase-free	 water	 on	 ice	 to	 avoid	 unexpected	






Name	 Origin	 Fabrication	 Dilution	
	Primary	antibodies	(IgG)		 	 	
E2F1	 rabbit		 Santa	Cruz	 1:500	
CDK4	 rabbit	 Santa	Cruz	 1:500	
GFP	(G6)	 mouse	 Santa	Cruz	 1:2000	
Histone	(H3)	 rabbit	 Santa	Cruz	 1:10000	
	 	 	 	
	Secondary	antibodies	(IgG)	 	 	
alexa	fluor® 488	anti-mouse goat	 Invitrogen	 1:15000	
alexa	fluor® 488	anti-rabbit	 goat	 Invitrogen	 1:15000	
alexa	fluor® 633	anti-mouse	 goat	 Invitrogen	 1:15000	







first	 to	 produce	 the	 cDNA	 corresponding	 to	 these	 mRNAs.	 Reverse	 transcription	 (RT)	
reaction	is	a	technique	that	allows	the	transcription	of	RNA	into	cDNA.	It	 is	done	thanks	to	
an	 enzyme,	 the	 reverse	 transcriptase,	which	 is	mixed	with	 random	primers	 to	 ensure	 the	
initiation	of	the	synthesis	of	cDNA	with	mRNA.	RT	also	requires	a	mix	of	nucleotides	for	the	
DNA	synthesis	and	various	RT	buffers	
The	 RNA	 solution	was	 standardized	 to	 a	 100	 ng/µL	 concentration	 in	 10	 µL	 of	 RNAse	 free	
water.	RTs	were	performed	in	20	µL	of	solution	per	200	µL	PCR	tubes,	with	10	µL	of	2X	RT	
master	mix	(see	table	2).	The	tubes	were	loaded	on	the	thermal	cycler	which	allows	the	RT	





































	 step	1	 step	2	 step	3	 step	4	
temperature	
(C°)	
25°C	 37°C	 85°C	 4°C	
time	
(minutes)	








Real-time	 Polymerase	 Chain	 Reaction	 (real-time	 PCR)	 or	 quantitative	 PCR	 (qPCR)	 is	 a	




primers	 (2,5	 µL	 forward	 primers	 and	 2,5	 µL	 reverse	 primers)	 for	 Chk1,	 E2f4	 and	 FoxM1	
(sequence	 available	 on	 table	 4)	 were	 used	 for	 the	 PCR,	 with	 5	 µL	 of	 cDNA	 sample.	 We	
performed	a	serial	dilution	until	a	final	amount	of	0,05	ng	of	cDNA.	Amplifications	were	done	

























































confluence	 at	 24	 hours	 and	 over	 80%	 after	 48	 hours.	 These	 two	 values	 were	 not	 so	
































As	 we	 wanted	 to	 evaluate	 the	 effect	 of	 the	 miR-31	 overexpression	 on	 the	 661W	 cell	
proliferation,	 we	 performed	 a	 transfection	with	 a	 plasmid	 expressing	 the	miR-31	 gene	 as	
well	as	the	Green	Fluorescent	Protein	(GFP)	gene	and	let	the	cells	express	these	genes	for	at	
least	 48	 hours.	With	 the	 reporter	 gene,	 we	 can	 detect	 the	 expression	 of	 the	 transfected	
plasmid	on	microscope,	and	therefore,	validate	the	transfection	in	the	cells.	










Cell	 lysate	was	 generated	48	hours	 after	 the	 transfection.	 Therefore,	 the	 transfected	 cells	
had	this	time	lapse	to	overexpress	the	miR-31	and	undergo	the	molecular	changes	that	we	
expected	to	 identify.	We	harvested	the	whole	cell	population	 in	 the	12-well,	 the	cells	 that	
received	an	efficient	transfection	and	the	ones	that	did	not.	
The	total	protein	concentration	for	each	sample	was	measured	with	BCA	assays	as	explained	
in	 materials	 and	 methods	 section	 and	 then	 diluted	 on	 the	 same	 concentration	 for	 the	
Western	Blot.	 	 The	 red	ponceau	staining	 revealed	 that	 the	WB	 transfer	on	 the	membrane	








GFP	 sequence	 was	 present	 in	 both	 plasmids	 and	 served	 to	 validate	 the	 efficiency	 of	 the	
transfection.	 The	 GFP	 protein	 is	 known	 to	 have	 a	 molecular	 weight	 of	 27	 kDa,	 which	
corresponds	precisely	where	 the	band	 is	 revealed	on	 figure	4.	We	can	 therefore	 conclude	














and	 white.	 (B,	 C)	 Green	 fluorescent	 protein	 (GFP)	 expression	 48	 h	 after	 miR-31	 transfection	 of	
661W	 cells.	 (E,	 F)	 GFP	 expression	 after	 GFP-scramble	 control	 transfection	 of	 661W	 cells.	 We	

























they	 are	 cell	 cycle	 proteins,	 and	we	 expected	 their	 level	 to	 decrease	 in	 the	 experimental	
condition,	compared	to	the	control	condition.	
Figure	5	 shows	 the	WB	analysis,	 the	 first	membrane	 (A)	was	 incubated	with	 E2F1	and	H3	
antibody	 solution	 and	 the	 second	 membrane	 (B)	 with	 CDK4	 and	 H3	 antibodies.	 The	


















Then,	 we	 compared	 and	 analysed	 with	 densitometry	 the	 intensity	 of	 the	 bands,	 which	
correspond	 to	 the	protein	concentration.	Then,	 the	values	 for	E2F1	and	CDK4	bands	were	
normalized	 with	 each	 corresponding	 H3	 protein	 signal.	 For	 each	 quadruplicate,	 we	




The	 densitometry	 (figure	 6)	 showed	 that	 the	 amount	 of	 E2F1	 protein	 was	 significantly	
reduced	 in	 the	 miR-31	 sample	 compared	 to	 the	 non-treated	 (NT)	 sample	 and	 the	 GFP-
treated	sample	(GFP	treated:	1.614	±	0.166	SEM,	n	=	4;	miR-31	treated:	0.444	±	0.108,	n	=	4;	
p	 =	 0.001).	 Regarding	 the	 CDK4	 densitometry,	 we	 observed	 a	 slight,	 but	 unsignificant	
difference	 between	 the	 GFP-treated	 and	 the	 miR-31	 treated	 samples.	 In	 conclusion,	 this	







































too	 little	RNA	concentration.	The	RNA	concentration	of	 the	 samples	varies	between	717.6	
ng/µL	 (for	 the	4th	GFP	 sample)	and	982.7	ng/µL	 (for	 the	3rd	GFP	 sample)	and	 the	260/280	
ratio	 varied	 between	 1.98	 (for	 GFP-4	 and	 miR-31-1	 samples)	 and	 2.01	 (for	 the	 HBSS-1	
sample).	We	normalized	the	concentration	of	the	following	samples:	HBSS-1,	HBSS-2,	HBSS-










of	 E2F1	 (A)	 and	 CDK4	 (B)	 were	 analyzed	 by	WB	 48	 h	 after	 the	 transfections	 of	 the	 different	
constructs.	Errors	bars	indicate	the	SEM.	Note	the	highly	significant	reduction	of	E2F1	in	the	miR-
















of	 the	 genes	 of	 interest	 (Chk1,	 E2f4,	 FoxM1)	 were	 normalized	 with	 a	 gene	 ubiquitously	
expressed	 in	 different	 cells	 (Mrl8).	 The	 values	 of	 the	 two	 treated	 conditions	 (GFP	





Chk1	 gene	 and	 E2f4	 gene.	 Unfortunately,	 with	 p	 values	 respectively	 at	 0.097	 and	 0.274,	
these	results	are	not	significant.	Concerning	the	FoxM1	gene,	the	expression	was	reduced	in	
experiment	(miR-31)	and	control	conditions	(GFP)	 in	comparison	to	the	NT,	so	this	 is	not	a	
relevant	 result	 for	 the	 experiment	 condition.	 The	 low	 expression	 fold	 change	 in	 the	 GFP-
treated	 samples	 may	 reveal	 a	 mishandling	 problem.	 Altough	 all	 these	 findings	 are	







Table	 5:	 Screenshot	 of	 Nanodrop®	 table;	 with	 Sample	 ID,	 nucleic	 acid	 concentration	












































finding	 does	 not	 yet	 lead	 to	 the	 full	 comprehension	 of	 cell	 death	mechanism	 in	 neuronal	
degeneration,	but	 it	makes	a	potential	 link	between	E2F1	protein	and	miR-31	 function,	 at	
least	 in	 661W	 cells.	 And	 because	 a	 reduced	 level	 of	 E2F1	 produce	 neuroprotective	 effect	
(18),	we	can	suggest	that	miR-31	overactivation	could	contribute	to	photoreceptor	survival.	
In	 the	 present	 results	 FoxM1,	 Chk1	 and	 E2f4	 are	 not	 significantly	 affected	 by	 miR-31	
overexpression.		We	may	also	suspect	them	to	be	indirectly	targeted	by	miR-31,	because	this	




(28),	 therefore,	 our	 hypothesis	 seems	 to	 be	 realistic.	 With	 this	 study,	 we	 come	 to	 the	
suggestion	 that	 if	 the	 low	 concentration	 of	miR-31	 in	Rd1	 retina	 could	 be	 increased,	 the	





could	 be	 increased,	 and	 so	 improve	 the	 expression	 of	 miR-31	 which	 may	 produce	 more	
considerable	 results.	 Considering	 this	 percentage	 of	 transfection,	 the	 gene	 expression	
decrease	 (or	 increase)	 is	 thus	much	more	pronounced,	because	 it	occurred	only	 in	around	
20%	of	the	cells	investigated.	Moreover,	all	our	analysis	was	performed	on	the	661W	cells	48	
hours	 after	 the	 transfection,	 a	 more	 extended	 period	 of	 time	 exposed	 to	 a	 miR-31	
overexpression	also	could	contribute	to	different	results.	
However,	 as	 this	 experiment	was	 done	 in	 a	 short	 amount	 of	 time,	WB	 analysis	 and	 qPCR	
could	not	be	done	for	all	the	proteins	and	gene	of	interest,	so	these	results	can	be	reinforced	
by	 validating	 the	 reduction	 of	 E2F1	 with	 qPCR.	 Next	 step	 could	 be	 to	 evaluate	 a	 miR-31	
overexpression	influence	on	other	cell	cycle	proteins.	The	fact	that	this	study	was	done	on	in	
vitro	661W	cell	line	also	has	to	be	taken	into	account,	as	all	this	should	be	confirmed	with,	











Reduced	miR-31	and	reactivation	of	cell	cycle	protein	 in	degenerating	Rd1	 retina	 led	us	 to	




neurodegeneration	 may	 be	 crucial.	 Obviously,	 further	 studies	 need	 to	 legitimate	 our	
findings,	 but	 this	 means	 that	 miR-31	 overexpresion	 could	 potentially	 produce	 a	
neuroprotection	 in	 degenerating	 cells.	 Next	 events	 seem	 to	 be	 promising	 as	 new	
pharmacological	 therapies	 could	 be	 developed	 to	 reduce	 the	 cell	 death	 process	 in	
degenerating	retinal	diseases.	
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